This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nicoletti, M. I. Articles by Giavazzi, R. Search for Related Content PubMed PubMed Citation Articles by Nicoletti, M. I. Articles by Giavazzi, R.

IDN5109, a Taxane with Oral Bioavailability and Potent Antitumor Activity¹

Department of Oncology, Laboratory of Biology and Treatment of Metastasis, Mario Negri Institute for Pharmacological Research, 24125 Bergamo [M. I. N., R. G.]; Department of Oncology, Laboratory of Cancer Pharmacology, Mario Negri Institute for Pharmacological Research, 20157 Milan [T. C., M. Z., M. D.]; Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, Chieti [C. R., C. M., S. S., M. B. D.]; and Indena S.p.A., 20139 Milan [A. R., P. M., E. B.] Italy

IDN5109 is a new taxane, derived from 14ß-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor cell lines expressing the multidrug resistant phenotype. Because, unlike paclitaxel, IDN5109 is a poor substrate for P-glycoprotein, we hypothesized that IDN5109 given p.o. could improve bioavailability compared with paclitaxel. Here, we studied the p.o. and i.v. pharmacokinetics of IDN5109 together with its antitumor activity. Using a high-performance liquid chromatography method, the bioavailability of IDN5109 was determined to be 48% after oral delivery. IDN5109 given p.o. was highly active against the two human ovarian carcinoma xenografts 1A9 and HOC18 (90–100% tumor regressions) and showed significant activity on the paclitaxel-resistant MNB-PTX1 xenograft (10% tumor regressions). The p.o. administration was as active as the i.v. route at doses reflecting the pharmacokinetic data. IDN5109 is the first taxane with good oral bioavailability and potent antitumor activity and represents a potential candidate for clinical investigation.

This article has been cited by other articles:

				C Pisano, L Vesci, R Fodera, F. Ferrara, C Rossi, M De Cesare, V Zuco, G Pratesi, R Supino, and F Zunino Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models Ann. Onc., September 1, 2007; 18(9): 1500 - 1505. [Abstract] [Full Text] [PDF]

				K. L. Hennenfent and R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Onc., May 1, 2006; 17(5): 735 - 749. [Abstract] [Full Text] [PDF]

				M. R. Bani, M. I. Nicoletti, N. W. Alkharouf, C. Ghilardi, D. Petersen, E. Erba, E. A. Sausville, E. T. Liu, and R. Giavazzi Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts Mol. Cancer Ther., February 1, 2004; 3(2): 111 - 121. [Abstract] [Full Text] [PDF]

				D. Sampath, C. M. Discafani, F. Loganzo, C. Beyer, H. Liu, X. Tan, S. Musto, T. Annable, P. Gallagher, C. Rios, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo Mol. Cancer Ther., September 1, 2003; 2(9): 873 - 884. [Abstract] [Full Text] [PDF]

				G. Cassinelli, C. Lanzi, R. Supino, G. Pratesi, V. Zuco, D. Laccabue, G. Cuccuru, E. Bombardelli, and F. Zunino Cellular Bases of the Antitumor Activity of the Novel Taxane IDN 5109 (BAY59-8862) on Hormone-refractory Prostate Cancer Clin. Cancer Res., August 1, 2002; 8(8): 2647 - 2654. [Abstract] [Full Text] [PDF]

				G. Taraboletti, G. Micheletti, M. Rieppi, M. Poli, M. Turatto, C. Rossi, P. Borsotti, P. Roccabianca, E. Scanziani, M. I. Nicoletti, et al. Antiangiogenic and Antitumor Activity of IDN 5390, a New Taxane Derivative Clin. Cancer Res., April 1, 2002; 8(4): 1182 - 1188. [Abstract] [Full Text] [PDF]

				G. Tortora, R. Caputo, V. Damiano, G. Fontanini, D. Melisi, B. Maria Veneziani, F. Zunino, A. R. Bianco, and F. Ciardiello Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity Clin. Cancer Res., December 1, 2001; 7(12): 4156 - 4163. [Abstract] [Full Text] [PDF]

				M. R. Vredenburg, I. Ojima, J. Veith, P. Pera, K. Kee, F. Cabral, A. Sharma, P. Kanter, W. R. Greco, and R. J. Bernacki Effects of Orally Active Taxanes on P-Glycoprotein Modulation and Colon and Breast Carcinoma Drug Resistance J Natl Cancer Inst, August 15, 2001; 93(16): 1234 - 1245. [Abstract] [Full Text] [PDF]